Sekar Kathiresan
CEOMale0.0Global Dominance: 0.00%
Sekar Kathiresan is a cardiologist and the CEO of Verve Therapeutics, a subsidiary of Eli Lilly. He led the recent groundbreaking study on a genetic editing treatment that significantly reduces LDL cholesterol levels, motivated by personal family health experiences with heart disease.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Sekar Kathiresan is the CEO of Verve Therapeutics and led the study on the genetic editing treatment.
Prevenção definitiva do colesterol? Cientistas mostram que pode ser possívelO Globo·
Brazil· 2026-05-27
Brazil· 2026-05-27
